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Numerous novel neuroscience-based drug targets have been identiﬁed in recent years. How- 
ever, it remains unclear how these targets relate to the expression of symptoms in central 
nervous system (CNS) disorders in general and psychiatric disorders in particular. To discuss this 
issue, a New Frontiers Meetings of European College of Neuropsychopharmacology (ECNP) was 
organized to address the challenges in translational neuroscience research that are impeding 
the effective development of new treatments. 
The main aim of this meeting was to discuss scientiﬁc insights, concepts and methodologies 
in order to improve drug development for psychiatric disorders. The meeting was designed to 
bring together stakeholders from academia, pharmaceutical industry, and regulatory agencies. 
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Here we provide a synopsis of the proceedings from the meeting entitled ‘New approaches to 
psychiatric drug development’. New views on psychiatric drug development were presented 
to address the challenges and pitfalls as identiﬁed by the different stakeholders. The general 
conclusion of the meeting was that drug discovery could be stimulated by designing new classiﬁ- 
cation and sensitive assessment tools for psychiatric disorders, which bear closer relationships 
to neuropharmacological and neuroscientiﬁc developments. This is in line with the vision of 
precision psychiatry in which patients are clustered, not merely on symptoms, but primarily 
on biological phenotypes that represent pathophysiological relevant and ‘drugable’ processes. 
To achieve these goals, a closer collaboration between all stakeholders in early stages of de- 
velopment is essential to deﬁne the research criteria together and to reach consensus on new 
quantitative biological methodologies and etiology-directed treatments. 























































































 1. Introduction 
The neuroscience ﬁeld is currently advancing insight
into the functional processes that underlie central ner-
vous system (CNS) derangement in psychiatric illness.
Such progress is the result of the development of more
advanced technologies in the ﬁeld, that include but
are not limited to neuroimaging, and various ‘omics’-
technologies like (epi)genomics, transcriptomics, pro-
teomics and metabolomics. Advances in other medical dis-
ciplines, such as clinical genetics and immunology, also
contribute to a better understanding of brain disorders. In
addition, innovative ways to quantify human and animal
behaviour, such as by means of clinical phenotyping, pro-
vide new translational research options. By applying sophis-
ticated biological mechanism based methodologies, an in-
creasing number of potential ’drugable’ CNS targets have
been identiﬁed which may potentially beneﬁt both clini-
cal management of psychiatric conditions and psychiatric
drug development in the future. However, a major concern
is that psychiatry has been unable to effectively exploit
the advances that neuroscience has yielded up to now. For
many novel neuroscience-based targets, it still remains un-
clear how they relate to symptoms or to clinical expression
of the disorders that make up psychiatric diagnostic enti-
ties. Therefore, stakeholders have yet to reach agreement
on how to move forward ( Hyman, 2016 ). 
The number of US Food and Drug administration (FDA)
approved new drugs in the last decades shows that psychi-
atric drug development is lagging behind compared to other
medical disciplines ( Bjornsson, 2016 ). To illustrate, in 2015
the total number of new registered drugs since 1975 was
33 in psychiatry versus 54 in neurology ( Bjornsson, 2016 ).
One aspect of the backlog of drug approvals in psychia-
try is a limited number of new mechanisms of action. In
many areas, such as neurology and oncology, drugs regu-
larly appear on the market that have novel or signiﬁcantly
modiﬁed mechanisms of action. In psychiatry, however, only
very few mechanisms of action have been introduced since
the development of monoamine reuptake inhibitors in the
eighties and nineties ( Bjornsson, 2016 ). This can be illus-
trated by the time course of an ‘innovation index’, which
can be deﬁned as the numbers of mechanism of action di-
vided by the number of registered drugs. Highly innovative
disciplines like immunology and oncology have innovation
indices of 40%–60%. It is interesting to compare the course ofdrug development in psychiatry and neurology, which both
deal with the same human organ, the brain. Fifteen years
ago, neurology and psychiatry both had innovation indices
of about 30%, meaning that in each disciplines three regis-
tered drugs shared a single mechanism of action. In neurol-
ogy, the index has since increased slightly to a stable level
of 35%, which reﬂects developments in multiple sclerosis,
epilepsy, Parkinson’s disease, stroke and other indications.
Psychiatry, however, has seen a steady decline of the in-
dex to about 20% (4–5 drugs per mechanism). Psychiatry and
cardiology are the only medical ﬁelds where the innovation
index has decreased since the beginning of this millennium
( Bjornsson, 2016 ). In cardiology, signiﬁcant advances were
made in preventive and innovative surgical and radiological
interventions. In psychiatry, however, improvements in cog-
nitive behavioural strategies and changes in the quality of
psychiatric care have offered no compensation for the slow
development of new psychiatric medications. 
The complexity of psychiatric drug development is re-
lated to several factors. First, there are pharmacological
restrictions due to the inviolability of the human brain. It
is difﬁcult to achieve blood-brain barrier (BBB) penetration
and to assess target engagement, and complex methods
are required to determine this (in)directly, such as in vivo
positron emission tomography (PET) imaging, functional CNS
tests, post-mortem studies and CSF sampling. Neurology is
helped in this respect by its focus on structural abnormal-
ities. Second, there is a disconnection between the deﬁni-
tion of the biological processes that underlie animal models
and human research, which has limited the identiﬁcation
of cross-species clinically relevant mechanisms. As a conse-
quence, insights from animal studies cannot be translated
directly into human drug targets. Innovative disease models
in neurology have proﬁted more from scientiﬁc advances,
particularly in genetics and immunology. Third, there is a
clinical heterogeneity in psychiatric disorders since their
classiﬁcation is based on the predominantly phenomenology
based Diagnostic and Statistical Manual of Mental Disorders
(DSM) and the neurobiological mechanisms for most disrup-
tions of CNS functions (behavioural, emotional, cognitive)
have only partly been unraveled. 
The treatment of a psychiatric patient may require a mul-
tifaceted and interactive approach. This is not an easy situ-
ation for drug development, and many large pharmaceutical
industries have shied away from this area. Nonetheless, be-
cause of the large social, economic, and personal burden of




















































































































msychiatric diseases, it remains important to develop inno- 
ative therapies, which are only effective for a part of the
roblem, or for a subgroup of patients, or which merely sup-
ort other pharmacological or psychosocial interventions. 
ithin this more narrowed scope, new approaches are nec- 
ssary and possible. Ultimately, this may lead to incremen- 
al improvements, which over time may provide more sci- 
ntiﬁc insights and larger clinical beneﬁts. Examples from 
eurology (stroke, multiple sclerosis, tumors) show that 
onsecutive small developments which in isolation are of- 
en highly disputed for their apparent lack of clinical rele-
ance for traditionally deﬁned patients, ultimately provide 
eal improvements for patients with newly deﬁned diagnos- 
ic characteristics. This incremental innovation also seems 
o be related to continuing support for clinical research net-
orks and infrastructure, which rapidly deteriorate if small 
uccesses are considered insigniﬁcant. 
In clinical disciplines with several-fold higher innovation 
ndices than psychiatry (like immunology and oncology), in- 
ovation is mainly drive by similar factors as in neurol-
gy. Occasionally, the advances are enhanced by a break- 
hrough that is taken up by several companies (with drugs 
hat are based on the new mechanism or a derived modi-
cation). However, most areas are able to sustain a slow 
ut steady supply of alternative or slightly improved medi- 
ations, on the basis of continuous drug improvements and 
linical research with more modest results and expecta- 
ions. 
To stimulate neuroscience-based adaptive approaches 
o psychiatric drug research and development, the Na- 
ional Institute of Mental Health (NIMH) launched the 
esearch Domain Criteria (RDoC) framework, which also 
upports new approaches to classiﬁcation of mental dis- 
rders ( www.nimh.nih.gov/research-priorities/rdoc/index. 
html ) ( Insel et al., 2010 ). The RDoC initiative asks inves-
igators to step back from diagnoses based on heteroge- 
eous clusters of symptoms and, instead, to focus on ba-
ic dimensions of functioning across the wellness spectrum 
hat might relate to various aspects of symptoms. The RDoC
ramework is centered around dimensional psychological 
onstructs and methods used to investigate and understand 
onstructs (termed ‘units of analysis’) including molecular, 
enetic, neurocircuitry and behavioural assessments. The 
DoC framework can facilitate new approaches for drug de- 
elopment by using the dimensional approach to test new 
rugs. 
The ECNP new frontiers meeting entitled ‘New ap- 
roaches to psychiatric drug development’ was held in Nice 
t 12 and 13 March 2017 and continued its discussions on
he 30th ECNP Congress in Paris later that year. The aim
f the meetings was to discuss scientiﬁc insights, concepts 
nd methodologies in order to improve drug development 
or psychiatric disorders. Translational gaps between novel 
argets, CNS functions and clinical phenomena have to be 
ridged if psychiatry wants to improve the condition of 
atients with psychiatric disorders by utilizing mechanism- 
ased CNS targets. Hence, it is crucial that neuroscientists, 
linicians, industry and regulators understand each other 
nd collaborate. The meeting was dedicated to discuss 
trategies to address this issue and to promote interactions 
nd discussions between different involved stakeholders 
rom academia, industry, clinicians, methodologists, regula- ors and patients. During the meeting, different stakehold- 
rs from academia, industry and regulatory agencies gave 
resentations which were followed by plenary discussions. 
ere, we provide an integrated review of the presentations
nd discussions of the meeting, which is written from the
uthor’s perspectives. This has led to the recommendations 
or new approaches in psychiatric drug development that 
re written below. 
. From disease category to pharmacology 
t the start of the meeting, a conceptual framework of
rug discovery in psychiatry was proposed (see Fig. 1 ). This
cheme is based on the notion that the CNS consists of neu-
onal networks, which use molecular mechanisms to express 
he brain’s various functions. Dysregulations of these func- 
ions cause neuropsychiatric symptoms, which form the ba- 
is of psychiatric disorders (see top of Fig. 1 ). Neuropsy-
hiatric drugs act on the molecular level (see bottom of
ig. 1 ), and thereby induce cascadic changes on brain net-
orks that ultimately affect their functionality. The targets 
f CNS active drugs (neurobiological receptors, enzymes 
tc.) are only indirectly related to changes of networks and
heir associated functions. The relationship between CNS 
unctions and DSM-constructs, which are often also remote, 
urther add to the complexity of psychiatric drug develop-
ent. 
Traditional psychiatric drug development is usually aimed 
t DSM-constructs, and therefore ignores the complex un- 
erlying cascade of events. Innovative drug development 
or psychiatric symptoms will require closer attention to the
nteractions between drug action and functional disorgani- 
ation, and to the adaptive nature of brain networks. This
ay include a reconsideration of psychiatric symptoms or 
henotypes, which are modulated by genetics (i.e. geno- 
ype), as dysregulations of functional networks. It will also 
equire the development and application of methods, which 
easures strategic hubs at different levels, i.e. molecular, 
ircuit, functional, of the cascadic processes. 
Fig. 1 is a schematic illustration which indicates that in-
ividual symptoms are more closely related to networks and
nderlying molecular biology than to multidimensional dis- 
ase constructs. Psychiatric disorders are currently mainly 
iagnosed based on qualitative assessment of symptoms, 
ather than quantitative analysis of aberrant neurobiology. 
n practice this means that the symptoms are well under-
tood, but the pathophysiology and therapeutic targets still 
emain unclear. As the patient will adapt to physiological 
r psychosocial changes and the disease may progress dur-
ng life, the distance between the underlying pathophysi- 
logy and the symptomatology increases. This directly in- 
uences drug development, since it is unclear whether the
athophysiology can predict the treatment response. In the 
uture, patients may be selected for different treatment 
ptions based on their symptoms and underlying biological 
roﬁle. 
For psychiatry, the most important outputs of brain 
unctioning are behaviour, emotion and cognition. Psychi- 
tric disorders inherently imply a difference between nor- 
al (adapted) and abnormal (maladapted). Therefore, as 
entioned in the introduction, the diagnostic framework 
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 has been dominated by the DSM and the International
Classiﬁcation of Disorders (ICD), which still play an impor-
tant role in deﬁning the boundary between well and unwell
( Millan et al., 2015 ). Another criticism has been made that
psychiatric disorders form a continuous spectrum with nor-
mality, in the way that ‘healthy’ subjects may display tran-
sient, mild and isolated symptoms of psychiatric conditions
such as anxiety, depressed mood and even psychosis. 
Network analysis can be used as a prediction for treat-
ment outcome. Neuroimaging methods, such as pharma-
cological magnetic resonance imaging (phMRI), electroen-
cephalography (EEG) and PET imaging, can be used as tools
for this prediction. The effects of psychopharmacological
agents on behavioural domains of large-scale networks can
be measured with phMRI, providing information about the
pharmacodynamics and underlying neurotransmitter mech-
anisms ( Honey and Bullmore, 2004; Khalili-Mahani et al.,
2017 ). Several factors need to be taken into account with
the standardization and reﬁnement of network analysis in
order to reduce their susceptibility to possible confounders.
The selection of the regions of interest (ROIs), for example,
can inﬂuence the accuracy of the inferred network organi-
zation, since the anatomical separation of the cortex may
inaccurately deﬁne the functional ROIs resulting in a dif-
ferent deﬁnition of the network nodes ( Smith et al., 2011 ).
Hierarchy of functional sub-regions based on spatially seg-
regated functional networks can be used for further reﬁne-
ment (connectopic mapping). Recently, Instantaneous Con-
nectivity Parcellation (ICP) has been shown as a speciﬁc
quantiﬁcation method to generate (sub)cortical parcella-
tions (top-down functional parcellation) ( van Oort et al.,
2017 ). Other reﬁnement methods are found in the implica-
tion of multiple imaging techniques together, such as corre-
lation maps that integrate both fMRI and PET data. Studies of the effects of psychiatric drugs will help to provide more
insights into key network phenomena ( Khalili-Mahani et al.,
2017 ). 
A potential helpful concept in dealing with the multi-
level complexity during CNS drug development is so-called
question-based drug development ( Cohen et al., 2015 ). This
basically translates all consecutive steps that connect the
drug to its effects (therapeutic or adverse), into questions
which need to be addressed during the drug developmental
process. Each step constitutes an uncertainty, which can be
reduced by appropriate measurements, in a study that em-
ploys the proper methodology and design. Table 1 provides
an indication of some typical questions for psychiatric drug
development, which follows the scheme of Fig. 1 , including
some suggested methods to (indirectly) address each ques-
tion. 
3. Precision psychiatry 
The heterogeneity of psychiatric disorders complicates their
deﬁnition, which is partly explained by genetic variabil-
ity. Evidence for different subtypes of psychiatric disorders
has been found, which gives an explanation for treatment
resistance in several indications, such as depression and
schizophrenia. 
Precision medicine is based on the clustering of individu-
als with psychiatric symptoms based on relevant biological
phenotypes (biotypes) instead of clinical phenomenological
classiﬁcations. An example of this approach is provided in
Fig. 2 ( Clementz et al., 2016 ). Since the behavioural do-
mains cover the entire neuropsychiatric spectrum, the con-
cept is to stratify patients beforehand on deﬁned subcat-
egories. Combinations (batteries) of clinical measurements
New approaches in psychiatric drug development 987 
Table 1 Question-based approach to steps that link the pharmacological activity of a central nervous system (CNS)-active drug 
to functional CNS-effects and related psychiatrically dysregulated functions. Methods are examples of approaches to measure the 
activity at the relevant step. EEG, electroencephalography; ERP, event-related potential; MRI, magnetic resonance imaging; PET, 
positron emission tomography. 
Consecutive step Question Method 
Target engagement Target site penetration Does the drug reach its site of 
action? 
Cerebrospinal ﬂuid 
concentration, PET imaging 
Target binding Does the drug bind to its 
molecular target? 
PET imaging 
Cascadic drug action Pharmacological activity Does the drug have its intended 
pharmacological effect? 
Neuronal excitability 
(EEG/ERP, MEG), target 
substrate, metabolomics 
Network activity How does the pharmacological 
effect inﬂuence a functional 
neurocircuit? 
Resting state functional MRI, 
EEG network analysis, PET 
imaging, cognitive and 
emotional processing tests 
probing speciﬁc circuits 
Neurophysiological activity 
(CNS function) 
Which CNS functions are 
affected by the drug (positively 
or negatively)? 




What are the effects of the 
drug on the psychiatric 
dysregulation of the affected 
CNS function? 
Psychiatric core symptom 
scores/ function tests 
Therapeutic window Clinical effect: beneﬁcial How does the drug affect 
patients who prominently 
express the core features of 
the disease? 
Clinical/patient/caregiver 
rating scales (subgroups) 
Clinical effect: adverse What are the adverse (CNS) 
effects of the drug (in the 
vulnerable subpopulation)? 




















































c  ead to clinical phenotypes, which have been anonymized 
eforehand. This method not only can distinguish different 
sychiatric disorders, but is also applicable to differentiate 
ontrol participants from patients. Here, in Fig. 2 , patients
ith a psychotic disorder underwent a deep phenotyping 
nalysis using cognitive, neuroimaging, oculomotor as well 
s genetic, clinical and clinical course markers, with multi- 
le markers collected per measurement category. None of 
hese biomarkers feel into any conventional diagnoses with 
nough power to be diagnostic. So the phenotypic charac- 
eristics of the individuals were used independent of the 
linical diagnosis to develop biologically based disease clus- 
ers. One might assume that ‘psychosis’ is analogous to a 
iagnosis of ‘congestive heart failure’ and that Biotypes 1, 
, and 3 are analogous to ‘cardiac’ vs ‘renal’ vs ‘pulmonary’
auses of congestive heart failure. This makes it incumbent 
o identify the distinctive and causal biology of the biotype,
roviding biological targets. 
Thus, precision medicine is a targeted approach to dis- 
ases where molecular diagnosis leads to better deﬁned, 
ndividualized treatments with improved outcomes ( Collins 
nd Varmus, 2015; Insel et al., 2015 ). Diagnostic tests based
n genetics or other molecular mechanisms can be used 
o better predict patients’ response to targeted therapy 
 Hamburg and Collins, 2010 ). However, there are several 
hallenges in genetics or genome-wide association studies 
GWAS) studies, such as pleiotropy which results in shared ommon genetic bases for different human traits. To over-
ome this, phenotypes with relatively high genetic correla- 
ions can be combined to enhance genomic prediction ac-
uracy in precision medicine ( Li et al., 2014; Maier et al.,
018 ). 
The concept of precision medicine has been well deﬁned
n other research disciplines, such as oncology and infec-
ious diseases. In these areas, ‘precision therapy’ is con-
eptually linked to molecular biological properties of the 
isease (or causative agent) that are relevant for the drug’s
echanism of action. For drug development in precision 
sychiatry it will also be essential that psychiatric biotypes
re based on ‘drugable’ characteristics, and to some extent
he patient will have to be matched to the most appropriate
rug. So far, however, clustering of psychiatric disorders has 
ot often been based on CNS-functions with close relation-
hips to neuropharmacological processes. At present, clus- 
ering is primarily based on neurobehavioural phenotypes 
hat are part of the clinical spectrum of psychiatric disor-
ers. Precision psychiatry is in line with the RDoC framework
f the NIMH ( Insel et al., 2015 ). 
Several attempts are currently made to deconstruct 
raditional symptom-based categories. Recently, the Psy- 
hiatric Ratings using Intermediate Stratiﬁed Markers 
PRISM) project received funding through the EU-Innovative 
edicine Initiative (IMI) to develop a quantitative biologi- 
al approach to the understanding and classiﬁcation of neu-
988 T.F. van der Doef et al. 
Fig. 2 Clustering patients based on neurobehavioural phenotype instead of diagnostic disorder ( Clementz et al., 2016 ) Reprinted 
















































 ropsychiatric diseases. The idea has been put forward that
clustering patients on the basis of the biology rather than
their clinical diagnosis will stimulate the discovery and de-
velopment of better treatments for patients ( Kas et al.,
2017 ). 
The PRISM project aims to identify and validate clinically
relevant biological substrates of neuropsychiatric symptom
constellations through the use of quantitative technolo-
gies. For that purpose, a clinical deep phenotyping study on
common traits, i.e. social withdrawal, sensory processing,
attention and working memory, shared between a multi-
factorial psychiatric disorder (schizophrenia) and a neu-
rodegenerative disorder (Alzheimer’s disease, AD) will be
performed to cluster patient groups based on quantitative
biological parameters, such as EEG and fMRI measures,
rather than on conventional diagnosis. Aligned preclinical
and clinical research methods will be implemented to pro-
vide the best predictive models for future drug discov-
ery studies and for validating human molecular landscaping
analyses to develop better understanding of the complex
pathophysiological relationships underlying these common
traits. It is aimed to provide novel classiﬁcation and assess-
ment tools for more effective identiﬁcation of the right pa-
tient for a given treatment of a speciﬁc symptom constel-
lation that translates into a better function and quality of
life ( Fig. 3 ) ( Kas et al., 2017 ). To provide new classiﬁcation
tools for neuropsychiatric disorders based on quantitative
biological parameters, schizophrenia and AD patients withhigh or low social withdrawal will be selected for a clinical
deep phenotyping study at the level of biological substrates
(genetic and epigenetics), EEG assessments (e.g., sensory
processing), neuroimaging (structural and functional MRI),
and behavioural assessments, e.g., smartphone application
(app) remote passive behavioural monitoring. A preclinical
platform with paradigms homologous to those assessed in
patients will be implemented for reverse translation of hu-
man ﬁndings. Together, these studies will provide new clas-
siﬁcation, assessment tools and approach strategies for so-
cial and cognitive performance across neuropsychiatric dis-
orders, clinically relevant substrates for treatment devel-
opment, and predictive, preclinical animal systems for sub-
sequent neurobiological and pharmacological testing ( Kas
et al., 2017 ). 
4. Pathophysiology biomarkers for 
psychiatric disorders 
At present, no diagnostic test or biological battery is avail-
able for psychiatric disorders, which are phenomenologi-
cally deﬁned. An important goal of phenotyping patients is
to develop improved biomarkers. Ideally, biomarkers should
be available for multiple mechanisms (1) they can function
as predictors of transition to psychiatric disorders in an at-
risk population, and (2) they predict and monitor treatment
response. 
New approaches in psychiatric drug development 989 
























































aThe term ‘biomarker’ has been widely used and can ap-
ly to a wide range of measurements including markers 
n biological material, e.g. serum, plasma, cerebrospinal 
uid, DNA, and mRNA, neuroimaging measurements includ- 
ng (ph/f)MRI and PET, cognitive test-batteries, and phys- 
ological measurements, such as heart rate, saccadic eye 
ovements and many more. Since one measurement has 
nsufﬁcient predictive value, combined methods are ex- 
mined to enhance the validity. For example, the results 
f markers in serum can be combined together with neu-
oimaging and physiological measurements. 
Thus, there are many potential biomarkers, and even 
ore possible associations with disease or patient charac- 
eristics. From a drug developmental perspective, biomark- 
rs are most informative if they represent well-deﬁned 
teps along the pathophysiology cascade ( Danhof et al., 
005 ). 
Driven by the boost of immunological research in many 
reas of medicine, there is growing interest in biomark- 
rs of the immune system in several psychiatric disorders. 
learly, this will have an effect on the design of clinical
rials, in which patients can be stratiﬁed on immunologi- 
al parameters. During the meeting, it was discussed that 
ajor depressive disorder is associated with an increase in 
eripheral markers like interleukin-6 (IL-6) and C-reactive 
rotein (CRP) ( Khandaker et al., 2017 ). Given that these im-
une markers are also increased in treatment resistant de- 
ression suggests that patients may be stratiﬁed based on 
heir serum proﬁle. A niche for new interventions for psy- 
hiatric disorders could be monoclonal antibodies (mAbs) 
hat are prescribed for other immune disorders. For ex- mple, IL-6 antibodies like siltuximab, which is prescribed 
or rheumatoid arthritis (RA), and IL-12/23 antibodies like 
stekinumab, which is used for psoriasis, may have anti-
epressant effect. Targeting the immune system may pro- 
ide a promising second line option for treatment of resis-
ant patients. 
Most of the biomarkers that are currently investigated 
n psychiatry, focus on neurophysiological and neurobehav- 
oral characteristics of DSM-based disease concepts. Clus- 
ering based on truly ‘deep’ psychopathological phenotyp- 
ng will also require measurements of the biomarker course
nd neuropharmacological processes that underlie derange- 
ents of behavioural, emotional, and cognitive functions. 
ther factors that have been studied are predictors of an-
idepressant treatment response like negative emotional 
ias in depression. Negative emotional bias has been asso- 
iated with depression and changes in emotional bias can
redict later clinical changes in symptoms. Recent studies 
uggests that antidepressant drug administration modulates 
motional processing in depressed patients very early in 
reatment ( Harmer et al., 2017, 2009 ). 
. Translational medicine approaches 
reclinical and clinical research should complement each 
ther. Preclinical research provides insight about potential 
echanisms underlying neuronal dysfunction and clinical 
esearch provides human relevance. To move the ﬁeld of
sychiatry forward, an integrated experimental medicine 
pproach is needed which integrates both preclinical and 





















































































































 clinical data. The lack of distinct endophenotypes of psy-
chiatric disorders has complicated the development of spe-
ciﬁc animal models. The question is how to develop cross-
species, clinically relevant quantitative phenotypes? During
the meeting, it was recommended to use reverse transla-
tion from clinical to preclinical research. The concept of
the reverse translational approach is that homologous hu-
man and animal endpoints, which are highly quantitative
and neutrally based, are being deﬁned to facilitate the
translation from humans to mice and vice versa. The ques-
tion remains how to address this homology? For example,
Perry and colleagues explored ‘open ﬁeld’ studies in ro-
dents and human patients at the level of face validity ( Perry
et al., 2009 ). In this study, exploratory behaviour of patients
with bipolar disorder and schizophrenia was quantiﬁed us-
ing a human open ﬁeld paradigm. Exploratory behaviour has
been well deﬁned in animal studies, but has been less stud-
ied in patients with psychiatric disorders. In the study of
Perry et al.( 2009 ), a difference was found in exploratory be-
haviour between healthy controls and bipolar patients, al-
though this was not demonstrated in schizophrenia. A sim-
ilar phenotype as that of the bipolar group was shown in
a mouse model with a genetic or pharmacological inhibi-
tion of the dopamine transporter compared to controls. Ac-
cording to these results the current amphetamine model
of mania, which is considered the standard model, may be
reﬁned. In addition, physiological measurements could be
considered, such as event-related potentials (ERPs), that
can be assessed both in rodent species and human, and may
be more closer related to pathophysiology of the disorders
at the level of neurocircuitry ( Kas et al., 2017 ). For drug
studies, reverse translational endpoints can be selected,
which characterize relevant aspects of psychiatric disorders
and are drug sensitive in animal models. In general, trans-
lational endpoints will be measures of distinct functions
and behaviours, rather than of disease constructs. Further
research is needed to identify homologous phenotypes in
human and animals. Ideally, these homologous phenotypes
should become quantitatively assessed and are associated
with processes underlying disease origin. 
6. Digital technology 
As mentioned previously, the multidimensional deﬁnition of
psychiatric disorders constitutes a problem for development
of psychiatric medications. On the one hand, this is re-
lated to the heterogeneity of phenomenology-based, psy-
chiatric diagnostic categories and their poorly understood
pathophysiology, which is probably just as heterogeneous.
On the other hand, drugs act at targets that interfere with
speciﬁc CNS functions, which in most psychiatric conditions
only play a partial or modulatory role. Precision psychiatry
could facilitate the switch from a symptom-based diagno-
sis to a biological-based diagnosis, as has been suggested
with the RDoC dimensions ( Insel et al., 2010 ). To identify
subgroups that have biological validity novel technology is
required. The question remains how digital technology may
help the ﬁeld forward. A current issue is the deﬁnition of
the read outs of the clinical research studies. It is ques-
tioned whether these are robust and clinical relevant and
whether the methods actually measure what is needed.For example, several clinical outcome assessment (COA)
tools like questionnaires are available to set a diagnosis
for psychiatric disorders and to evaluate symptom severity.
However, most questionnaires are subjective and/or do not
provide quantitative outcomes. Second, since psychiatric
disorders are complex brain disorders is it difﬁcult to grasp
these brain deﬁcits in the existing COAs like questionnaires.
As such, the questionnaires may not cover the whole spec-
trum of cognitive, behavioural or emotional functions as this
is far too complex for a questionnaire. This may be the niche
for novel technology. 
New technologies are required to provide quantitative bi-
ological parameters to deﬁne patient subgroups. Advanced
techniques in the ﬁeld, such as neuroimaging, and the omics
technologies may provide suitable measures of relevant bio-
logical processes. Digital technologies and innovative meth-
ods can also be used to measure functionally and clinically
relevant parameters in patients’ daily lives. This could in-
clude medical devices, more sophisticated computerized
batteries of neurocognitive tests, and mobile health appli-
cations (apps). There is growing interest for research us-
ing smartphone data or mobile healthy apps. This leads to
all kind of new possibilities, from actively asking patients
how they feel at different time points a day, which is called
ecological momentary assessment ( Shiffman et al., 2008 ),
to monitoring a subject’s spontaneous behaviour. Passive
monitoring can result in collecting multiple data including
location using GPS signaling, time, social behaviour mea-
sured by telephone calls and duration, and use and content
of text-messenger applications and social media platforms
( Marzano et al., 2015; van Os et al., 2017 ). When these data
sources are combined, a social rhythm of a subject can be
identiﬁed. If anomalies in these rhythms occur, this gives
relevant information which may help to predict or identify
functional deﬁcits like social withdrawal. This could help
predict psychiatric illness exacerbation, or the responsive-
ness to drugs that are targeted at functional derangements
rather than nosological entities. 
At present, real-life (‘smartphone’) research in psychia-
try is still in its infancy, and for most psychiatrically relevant
behaviours, emotions and functions, validated ambulatory
measurements are still unavailable. There are many techni-
cal and methodological as well as ethical issues. As such, it
is recommended to have validation studies in the upcoming
years to gain experience with the procurement and analysis
of these big data sets. At present, there are already sev-
eral successful examples like the development of devices
to monitor treatment compliance, and devices to measure
Patient Reported Outcomes (PROs), which is highly encour-
aged by regulatory agencies. For example, Wacean, an on-
line platform created by the Dravet Syndrome Foundation,
is a patient-driven tool for data capture of PRO assessment.
In order to succeed, the novel technology including apps
measuring behaviour should be pre-validated by regulatory
bodies before they can be accepted as endpoint in clini-
cal trials. The European Medicines Agency (EMA) has an ex-
pedite drug development program to facilitate this request
and is used to accelerate the process for initiatives at this
level. It is getting ever easier to build smartphone applica-
tions and web-based tools for psychiatry or drug develop-
ment. This is already leading to an abundance of methods,
most of which are unvalidated and incomparable to other


















































































































aimilar tools. There is an increasing need for more struc-
ured approaches. A centralized European network would 
e helpful to resolve questions by offering communication 
etween groups with past experiences. There is also a need 
or harmonization and development of standards, compara- 
le to ICH-GCP. 
. Regulatory and advisory agencies 
t the ECNP meeting, academia, industry and regulatory 
gencies were brought together during focused discussions. 
here was agreement that collaboration of academia and in- 
ustry with regulatory and advisory agencies together could 
e strengthened. In general, academia, biotech and phar- 
aceutical industries are the drivers of innovation on clin- 
cal endpoints and have a close collaboration in which they
an easily connect and discuss these outcome measure- 
ents. Moreover, these groups are the source of the large
roups of volunteers needed to advance the ﬁeld, but this 
ill require common projects and collaborations. Regula- 
ory and advisory agencies (RAs) advise on clinical end- 
oints to include in study protocols and provide approval 
or speciﬁc clinical endpoint measurements. They are the 
ain drivers for the ﬁnal COA and COA instrument selec- 
ion. In principle, regulatory agencies are open to sugges- 
ions from academia and industry, but the outcome of the
tudy needs to be predeﬁned. Problems occur when inno- 
ative outcome measurements are developed by academia 
nd industry without timely communication with the reg- 
latory agencies. Without appropriate validation and prior 
greement, it may be difﬁcult to achieve regulatory accep- 
ance of such novel methodologies in drug development. It 
ight be worthwhile to perform validation studies examin- 
ng COAs that can be used in further development plans. 
s such, pre-competitive strategies can be advised to dif- 
erent pharmaceutical companies with the aim to develop 
pplicable instruments for speciﬁc indications (IMI funded 
rojects). 
Another issue is that the deﬁnition of innovative end- 
oints in relation to diagnostic or therapeutic objectives, 
hich is provided to RAs, is often not speciﬁc enough.
herefore, the disease-speciﬁc guidance issued by RAs are 
pen to discussion, and consequently COA instrument selec- 
ion requires a more interdisciplinary approach. There is a 
endency to replicate previous study designs for new drugs, 
hich leads to repetition of the same problems that oc- 
urred in the past and refutes innovation. The use of scales
hich in themselves are well accomplished, may be unac- 
eptable for RAs if they are used for other indications for
hich they were not validated. For example, batteries in 
ementia clinical trials like the cognitive subscale of the 
lzheimer’s Disease Assessment Scale (ADAS-Cog) ( Rosen 
t al., 1984 ) has been designed to measure cognitive out-
ome in AD, but its sensitivity varies with disease severity 
ith poor sensitivity in early AD (i.e. large ceiling effects on
ost items of the scale in patients with Mini-Mental State
xamination (MMSE)’s above 20 ( Karin et al., 2014 ). Despite
his knowledge, clinical trials continue to use this measure 
n all stages of the illness limiting the ability to detect a
rue drug effect ( Frölich et al., 2011; Gold et al., 2010 ). Learnings from success and failure in innovative drug 
evelopment in neurosciences, shows that more emphasis 
hould be placed on development of more sensitive end-
oint/outcome measures and validation of these outcome 
easures in experimental medicine studies ahead of phase 
 and 3 studies with drug candidates, aiming for markers
nd outcome measures that are sensitive (i.e. disease and
harmacological activity) and able to capture pathophys- 
ologically relevant phenotypes. In an early stage of drug
evelopment, the development of new tests and outcome 
easures and validation of these measures needs to be per-
ormed in cooperation with regulatory agencies. This is par-
icularly relevant for new methods that will be used not
nly for internal decision making, but also for registration
r marketing. Regular communications with the FDA and 
he EMA, and collaborations or pre-competitive initiatives 
etween academic, industry and funding bodies, are also 
mportant to exchange views and share expertise. 
Thus, collaboration between academy and industry with 
egulatory agencies in an early stage is warranted to deﬁne
he research criteria together for clinical endpoints. This 
s essential if the new drugs require gradual adaptations
f study designs and methodologies, and of clinical indica-
ions and effects. Such fundamental developments may also 
ave important consequences for patients and clinicians, 
nd sometimes even for the health care system and society.
imilar changes also occurred when currently available psy- 
hiatric medications became widely used. Therefore, these 
mportant stakeholders should also be involved in design- 
ng studies, selective methods and redeﬁning relevant out- 
omes. 
. Patient participation 
rugs are intended to treat individuals who seek help, and
heir needs are the central drivers of drug development.
his must be realized if new approaches are adopted to
elect drug targets, design diagnostic tools and redeﬁne 
isease entities. New diagnostic or therapeutic approaches 
ay affect many aspects of patients’ lives. At the most ba-
ic level, this will inﬂuence their trust in the treatment and
nﬂuences drug compliance. Psychiatric disorders are often 
hronic after a ﬁrst episode and present sometimes for a
ifetime, which means that a long-term maintenance phar- 
acological treatment may be required. In order to fulﬁll
he drug compliance, the pharmacological treatment should 
e attractive and easy to administer. However, the smell,
aste, or effect of the drug should be not too tempting to
revent substance misuse or addiction. New tools to moni-
or aspects of behaviour also pose new ethical and societal
uestions. Diagnostic classiﬁcations have a major impact on 
he position of patients in society, and new ways to deﬁne
disease’ will also turn new people into ‘patients’. 
In all areas of medicine the principles of Early Detec-
ion and Early Treatment are a given. Now that evidence
s emerging that Early Treatment will result in better over-
ll recovery from a mental illness, psychiatry will have to
espond with an emphasis on both early detection and early
reatment along with a full range of treatments which in-
lude cognitive, psychological and neurostimulation as well 
s pharmacological forms, for help-seekers. 
992 T.F. van der Doef et al. 
Table 2 Research ideas for new approaches in psychiatric drug development. 
1 Deconstruct the multidimensional characteristics of psychiatric disorders into distinct neurobiological functional 
abnormalities. 
2 Cluster patients primarily on biological phenotypes that represent pathophysiologically relevant and ‘drugable’ 
processes. 
3 Develop and validate biomarkers that underlie the pathophysiology of psychiatric disorders and/or which represent 
pharmacological processes. 
4 Base experimental approaches in humans on reverse translation from clinical to preclinical research, focusing on 
evolutionarily preserved neurobiological and neuropharmacological systems. 
5 Digital technologies can be useful to quantify pathophysiologically relevant biological parameters, which can provide 
mechanism-based characterizations of patient subgroups and clinical effects. 
6 Collaboration between academy and industry with regulatory agencies in an early stage is recommended to deﬁne the 
research criteria together for clinical outcome endpoints. 
7 Involve patients in the design of new diagnostic tools and therapeutic approaches, clinical trials and deﬁnition of 





































































 It is recommended therefore that patients and patient
societies are closely involved in the design of clinical trials
and deﬁnition of clinical outcome measurements, prefer-
ably in an early stage. Although much has been changed
in consideration of the patients’ perspectives during the
last decades, it is not the current standard in each clinical
trial to include patients and patient societies. In some Eu-
ropean research institutes the involvement of patients has
been standard practice already. For example, the National
Institute for Health Research (NIHR) Maudsley Biomedical
Research Centre (BRC) has a Service User Advisory Group
which consists of people with experience of mental illness
and an interest in mental health research. Researchers from
the NIHR Maudsley BRC discuss their study design with this
advisory committee to receive feedback in an early stage
(before ﬁnalization of the protocol). 
Individuals with a disorder, caregivers, and health profes-
sionals do not always have the same views on the impact of
the disease symptoms or adverse drug effects. The appreci-
ation of drug-induced sedation for instance can differ con-
siderably between patient, caregiver, employer and physi-
cian. New diagnostic or therapeutic approaches may have
complex unexpected consequences for the patient and his
or her social environment. This largely unexplored territory
may be particularly suitable for new digital technologies,
which can only be designed in close interaction with the pa-
tients and their social structures. 
9. Discussion 
Based on the presentations and discussions in the meeting,
several suggestions for new approaches to drug develop-
ment in psychiatry are summarized in Table 2 . 
How can we put these new approaches into practice?
When psychiatric disorders are classiﬁed according to the
principle of precision psychiatry, patients can be clustered
on mechanistic biological phenotypes. Measures of phar-
macological responsiveness could strengthen the links with
‘drugable’ targets. The knowledge about the biological phe-
notypes is largely driven by the availability of appropriate
methods, which are continuously renewed by technological
innovations. The outcome measurements of available tech-
niques, such as neuroimaging, ‘omics’ and ‘smartphone’applications, may be integrated in order to assess the bi-
ological phenotypes and to provide simple, and accurate
biomarkers. In addition, reverse translation from clinical to
preclinical research may help to unravel the biological back-
ground of important aspects of psychiatric disorders. When
models that can translate between preclinical and clinical
results are also drug sensitive, the effects of pharmaceuti-
cals of different species can be more easily translated as
well. 
If drug development will follow this pattern, patients
may be stratiﬁed for different treatment options based on
their symptoms and underlying biological (drug-sensitive)
proﬁles. A new approach to drug development may require
closer attention to the interactions between drug action and
functional disorganization. This may include a reconsidera-
tion of psychiatric symptoms as dysregulations of functional
networks. 
Novel approaches to psychiatric drug development af-
fect many aspects of psychiatry. This can only be accom-
plished if all stakeholders collaborate at early stages of drug
development, when new methodological approaches often
still largely need to be validated. Not only academia and
industry should work closely together with regulatory and
advisory agencies, but societies of patients and represen-
tatives should also be involved. In order to achieve these
ambitious goals, communication between the stakeholders
is key. This can be accomplished by regular meetings like
the ECNP meetings and conferences. Furthermore, commu-
nication can be strengthened via technology platforms with
the aim to share expertise. As an example, the Innovative
Medicines Initiative (IMI) provides a pre-competitive plat-
form to initiate such collaborations. 
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